Dr. Topalian on Biomarkers for Anti- PD-1 Therapies in Melanoma

Suzanne L. Topalian, MD
Published: Thursday, Feb 12, 2015


Suzanne Topalian, MD, professor of surgery and oncology, John Hopkins Medicine, and director of the melanoma program, Sidney Kimmel Comprehensive Cancer Center,  compares biomarker detection for anti- PD-1 therapies like nivolumab to anti-CTLA-4 therapies like ipilimumab for the treatment of melanoma.

PD-1 and PD-L1 blocking drugs are more active at the tumor site, says Topalian. To determine markers for PD-1 drugs , investigators must look at the tumor itself and correlate them with clinical outcomes.  Anti-CTLA-4 therapies have a global impact on the immune response, so markers such as PD-L1 may not be relevant.  


Suzanne Topalian, MD, professor of surgery and oncology, John Hopkins Medicine, and director of the melanoma program, Sidney Kimmel Comprehensive Cancer Center,  compares biomarker detection for anti- PD-1 therapies like nivolumab to anti-CTLA-4 therapies like ipilimumab for the treatment of melanoma.

PD-1 and PD-L1 blocking drugs are more active at the tumor site, says Topalian. To determine markers for PD-1 drugs , investigators must look at the tumor itself and correlate them with clinical outcomes.  Anti-CTLA-4 therapies have a global impact on the immune response, so markers such as PD-L1 may not be relevant.  




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x